The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.
NCT ID: NCT05097274
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2015-10-15
2032-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DNA repair gene mutation carriers
* Newly diagnosed with prostate cancer (any Gleason score, any stage, any PSA)
* Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy
* Patients on active surveillance, with a PSA doubling time of 6 months or less
MRI pelvis or CT imaging under clinical management for Pr Ca
Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
Whole body bone scan imaging
bone scan of the whole body (under clinical diagnosis).
PET-CT imaging
Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI pelvis or CT imaging under clinical management for Pr Ca
Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
Whole body bone scan imaging
bone scan of the whole body (under clinical diagnosis).
PET-CT imaging
Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over the age of 18
* Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either:
* At a new diagnosis
* Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy
* Patients on active surveillance with a PSA doubling time of 6 months or less
Exclusion Criteria
* Known metastatic prostate cancer, both local and distant
* Patients who have received any oncological treatment within the last six months
* Patients on any investigational drug treatment
* Patients on steroids
* Known history of inflammatory/infective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease)
* Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers, aneurysm clips, claustrophobia)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Research UK
OTHER
National Institute for Health Research, United Kingdom
OTHER_GOV
Institute of Cancer Research, United Kingdom
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rosalind A Eeles, FRCP FRCR
Role: PRINCIPAL_INVESTIGATOR
Institute of Cancer Research and Royal Marsden Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Genetics Unit, Royal Marsden Hospital
London, Sutton, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCR4131
Identifier Type: -
Identifier Source: org_study_id